Manganese Overdose: Causes, Symptoms, and Treatment

Manganese overdose, clinically called manganism, is a form of poisoning that damages the brain’s movement-control centers and produces symptoms strikingly similar to Parkinson’s disease. The metal accumulates preferentially in a deep brain structure called the globus pallidus, disrupting the signaling chemicals that coordinate movement and mood. Although the body needs trace amounts of manganese for normal enzyme function, it maintains tight control over how much gets absorbed and excreted under healthy conditions.¹ When that control system is overwhelmed or bypassed, the consequences can be severe and, in some cases, irreversible.

How People End Up With Too Much Manganese

Manganese poisoning rarely comes from food. The body’s gut-based absorption controls work well enough that dietary excess alone almost never causes toxicity. The problem arises when manganese enters the body through routes the gut cannot regulate, or when the liver loses the ability to clear it.

The most well-documented route is occupational inhalation. Workers in mining, ore processing, ferroalloy production, and welding breathe in manganese-containing dust or fumes that travel from the lungs directly into the bloodstream and, from there, into the brain.² Welders are a particularly studied group. One cross-sectional study of welders found average breathing-zone manganese concentrations well above safety thresholds and confirmed measurable neurobehavioral and cognitive impairments in the exposed workers.³ Poorly ventilated workspaces dramatically increase risk, with individual case reports of full-blown neurological disease in welders who worked in confined spaces.²

A second major route is intravenous nutrition. Patients receiving total parenteral nutrition (TPN) bypass the gut entirely, meaning any manganese added to the nutrient solution enters the blood without the usual absorption filters. A review of case reports found manganese toxicity developing in TPN patients in as few as 15 days, with wide variation depending on the dose and duration of supplementation.⁴ One illustrative case involved a 38-year-old woman on chronic TPN who developed confusion, falls, lethargy, and Parkinson-like features, with characteristic brain MRI changes pointing squarely to manganese accumulation.⁵

Contaminated drinking water is a less dramatic but potentially widespread route. An analysis of over 43,000 wells across the United States estimated that roughly 2.6 million people may be drinking groundwater with manganese concentrations above 300 micrograms per liter, particularly in areas near rivers or with organic-carbon-rich soil.⁶ The World Health Organization once set a drinking-water guideline of 400 micrograms per liter but later discontinued it, reasoning that health-based values were above typical drinking-water concentrations. Critics have argued that conclusion was premature, since many tens of millions of people worldwide drink water exceeding that level, and recent research suggests even that guideline may have been too lenient.⁷ That said, a study of people in northern Germany exposed to well water with manganese levels up to 2,160 micrograms per liter for up to 40 years found no clear neurological effects, suggesting that oral exposure works very differently from inhalation.⁸ The gut’s absorption-limiting mechanisms appear to provide substantial protection, though children may be more vulnerable to the same water concentrations than adults.

A Less Obvious Route: Illicit Drug Manufacturing

An unusual cluster of manganese poisoning cases has emerged in Eastern Europe and a few Western countries among people who inject a homemade psychostimulant called ephedrone (methcathinone). The drug is made by oxidizing pseudoephedrine or ephedrine with potassium permanganate, a manganese-containing chemical.⁹ Because the crude product is injected intravenously with residual manganese still present, users develop a Parkinson-like syndrome within months. The pattern is consistent: slowed movement, difficulty speaking, dystonia, and impaired balance, all unresponsive to standard Parkinson’s medication.¹⁰

What Happens Inside the Brain

Manganese preferentially accumulates in the basal ganglia, a group of brain structures that help coordinate voluntary movement. Within those structures, the globus pallidus bears the heaviest burden.¹¹ Once inside brain cells, manganese concentrates in the mitochondria, the structures that generate cellular energy. At high levels, it binds to the chemical substrates those mitochondria need and effectively stalls the energy-production machinery. This triggers inflammatory signals and, eventually, cell death.¹²

The damage also disrupts chemical signaling. Manganese exposure reduces the activity of the enzyme that makes dopamine and impairs the transporters that handle dopamine at the synapse, leading to deficient dopamine signaling in movement-related circuits.¹³ Simultaneously, it alters the balance of another signaling chemical, GABA, by interfering with its reuptake. The overall effect is a double hit: too little dopamine for smooth movement and too much GABA activity adding further inhibition. The oxidative stress generated by excess manganese compounds the problem by damaging cells through pathways involving inflammation and structural changes to proteins.¹⁴ Over time, this leads to neuronal loss and characteristic changes to brain support cells in the basal ganglia.¹⁵

Recognizing the Symptoms

Manganism typically creeps in rather than announcing itself. The early stage is dominated by psychiatric and nonspecific complaints: headache, fatigue, sleep trouble, irritability, and emotional swings. Some patients become anxious or depressed. This phase can last months to years before the more recognizable motor symptoms appear.¹⁶ The psychiatric onset is one reason manganese poisoning is often missed early; a welder or factory worker who feels irritable and tired is unlikely to suspect a metal is accumulating in his brain.

When the motor phase arrives, it brings stiffness, slowed movement, trouble with balance, and sometimes dystonia, where muscles lock into abnormal postures. One hallmark is the “cock walk,” a distinctive gait pattern in which the person walks on their toes with the trunk erect and elbows flexed, as though strutting.¹⁷ A documented case of a welder with manganese-induced parkinsonism showed slowed eye movements, a mask-like face, cogwheel rigidity, and a low-frequency tremor alongside this gait.¹⁸

The sequence matters clinically. In Parkinson’s disease, the motor problems come first and psychiatric symptoms appear later. In manganism, it is the reverse: psychiatric symptoms dominate early, and the motor syndrome develops afterward.¹⁹

How Manganism Differs From Parkinson’s Disease

The resemblance to Parkinson’s disease is close enough to cause confusion, but several features set manganism apart. Resting tremor, the classic shaking-at-rest seen in Parkinson’s, is much less common in manganism. Dystonia is more frequent. Patients with manganism tend to fall backward rather than forward. And a telling clinical clue is the response to levodopa, the cornerstone Parkinson’s drug: manganism patients do not improve on it.²⁰ A double-blind study of welders with parkinsonism confirmed that levodopa was ineffective, and the researchers suggested that this lack of response could itself serve as a distinguishing feature.²¹

The reason for this difference lies in where the damage happens. Parkinson’s disease primarily destroys dopamine-producing neurons in the substantia nigra. Manganism primarily damages the globus pallidus, a structure downstream in the same circuit. Because the dopamine-producing cells are relatively spared, giving more dopamine raw material (which is what levodopa does) does not help.

Diagnosis

Brain MRI is the most useful diagnostic tool. Manganese deposits produce a bright signal on a specific type of MRI sequence (T1-weighted images), particularly in the globus pallidus. This bright signal is distinctive enough to strongly suggest manganese accumulation when seen in the right clinical context.²² Patients with liver disease and those on parenteral nutrition frequently show this same MRI pattern when manganese builds up.²³

Blood manganese levels can confirm recent or ongoing exposure, but they have real limitations. For people with long-term, low-level exposure or those whose exposure ended some time ago, neither blood levels nor MRI reliably separates who was exposed from who was not.²⁴ Blood levels reflect current circulating manganese but say little about how much has already been deposited in the brain. That creates a frustrating diagnostic gap for former workers or patients evaluated long after exposure stopped.

Who Is Most at Risk

Beyond occupational groups and TPN patients, people with chronic liver disease face a particular danger. The liver is the body’s primary route for clearing manganese, excreting it into bile. When the liver fails, manganese from a perfectly normal diet can accumulate to toxic levels. Studies of patients with biopsy-confirmed cirrhosis have shown significantly elevated blood manganese concentrations and the same characteristic bright signals on brain MRI seen in occupationally exposed workers.²⁵ One study found that median blood manganese in cirrhosis patients was more than three times higher than in healthy controls, and that the intensity of the brain MRI signal correlated with blood levels.²⁶ This has led researchers to propose that manganese accumulation may contribute to the neurological symptoms traditionally attributed to hepatic encephalopathy itself.

Iron deficiency also appears to amplify risk. Iron and manganese share some of the same absorption and transport pathways, so when iron levels are low, the body absorbs more manganese than usual. One case report highlighted chronic manganese neurotoxicity in a cirrhosis patient whose iron-deficiency anemia likely worsened the metal’s accumulation.²⁷

A small number of people carry genetic mutations that break the body’s manganese-clearance machinery entirely. Mutations in the SLC30A10 gene, which codes for a manganese transporter, cause a recessively inherited disease featuring parkinsonism, dystonia, high blood manganese, chronic liver disease, and an unusual finding: elevated red blood cell counts (polycythemia).²⁸ Prior to discovery, SLC30A10 had been assumed to transport zinc; the genetic findings revealed it is actually a manganese transporter whose loss traps the metal inside cells.²⁹ A second gene, SLC39A14, has since been linked to a similar syndrome. Loss-of-function mutations in either gene raise manganese levels in blood and brain and cause severe neurotoxicity, often beginning in childhood.³⁰

Children and Developmental Effects

Young children appear especially sensitive to manganese. Their brains are still developing, they absorb a higher proportion of ingested manganese than adults do, and their excretion systems are immature. The concern is not classic manganism with motor symptoms but subtler effects on cognition and behavior.

Studies have found that children drinking water with manganese at or above roughly 240 micrograms per liter for three or more years performed worse in language, math, and overall school achievement compared with less-exposed peers. Lower IQ scores and poorer results on neurobehavioral tests were consistently linked to higher manganese levels.³¹ A systematic review and meta-analysis reinforced these findings, concluding that higher manganese exposure had a negative effect on cognitive and motor development in children under six. In older children aged six to eighteen, hair and drinking-water manganese levels, though not blood levels, were associated with poorer cognitive and behavioral outcomes. The meta-analysis estimated that a tenfold increase in hair manganese was linked to roughly a two-and-a-half-point drop in full-scale IQ.³²

Research continues to focus on early-life overexposure and the vulnerability of the developing frontal cortex, which governs planning, attention, and impulse control.³³ This is an area where the public health implications stretch well beyond the factory floor and into communities served by private wells with naturally high manganese.

Treatment Options

The first and most important step is removing the source of exposure. For a welder, that means changing work conditions or leaving the job. For a TPN patient, it means reducing or eliminating the manganese component from the nutrition formula. For someone with liver failure, the treatment may ultimately be a liver transplant. In one reported case, an eight-year-old girl with chronic liver failure and manganese-related dystonia had complete resolution of symptoms, normalization of brain MRI findings, and return of blood manganese to normal after receiving a liver transplant.³⁴

For patients who need active treatment to lower manganese in the brain, the most promising drug studied so far is para-aminosalicylic acid (PAS), a medication originally approved as an anti-tuberculosis drug. A remarkable 17-year follow-up of a single patient with severe occupational manganism showed that PAS treatment significantly improved symptoms and restored normal handwriting. At her most recent evaluation, the patient had essentially normal clinical, neurological, and MRI findings aside from a minor gait issue.³⁵ Animal studies have shed some light on how PAS works. In rats given high-dose PAS for several weeks, manganese levels dropped significantly in the liver, heart, spleen, pancreas, and eventually in multiple brain regions. The drug also helped restore normal levels of iron and copper that had been disrupted by the manganese overload.³⁶ More recent laboratory research has explored combining PAS with another chelating agent, CaEDTA, as a strategy that may be more effective at dislodging manganese from brain binding sites than either drug alone.³⁷

Standard Parkinson’s drugs, including levodopa, are not helpful and cannot be considered a treatment for manganism. Supportive approaches, including physical rehabilitation and cognitive training, are increasingly recognized as important for patients whose neurological damage has already occurred. Structured exercise, motor rehabilitation, and cognitive stimulation can improve quality of life and function in patients with movement disorders linked to metal toxicity.³⁸

How Much Recovery Is Realistic

The outlook depends heavily on how far the disease has progressed before exposure stops. In some cases, removing the manganese source leads to full resolution. One case report described a welder whose symptoms and brain MRI abnormalities completely resolved within a year of stopping exposure.³⁹ The child with liver failure who received a transplant similarly recovered fully.

But the picture is not always this encouraging. Neuropathological studies of patients with chronic manganese poisoning have found that neurological symptoms can persist even after brain manganese levels return to normal, suggesting that permanent structural damage has already occurred.⁴⁰ This means that in advanced cases, clearing the metal from the brain does not necessarily undo the harm. There is also an unsettling possibility raised by case reports: some patients who initially recover from manganism may later develop idiopathic Parkinson’s disease, suggesting that past manganese damage could make the brain more vulnerable to subsequent neurodegeneration.³⁹

The practical message here is that early detection matters enormously. A welder with headaches, mood changes, and sleep disruption who has reason to suspect manganese exposure should not wait for motor symptoms. By the time the distinctive gait and stiffness appear, significant and potentially irreversible brain damage may already be present. For clinicians, the combination of occupational exposure history, psychiatric symptoms, and the characteristic MRI pattern should be enough to act on, even before formal motor findings emerge.

When the Body’s Own Clearance System Breaks Down

Most discussions of manganese toxicity focus on exposure, but the liver’s clearance role deserves separate emphasis because it reframes who should be concerned. A person with healthy liver function can handle a surprisingly wide range of dietary manganese without trouble, precisely because bile excretion efficiently removes it. But anyone with significant liver disease, from chronic hepatitis to advanced cirrhosis, is operating with a compromised manganese disposal system. The metal accumulates from ordinary food, at ordinary levels, simply because the exit route is blocked.

Researchers studying cirrhosis patients found the highest manganese concentrations in the caudate nucleus, followed by the quadrigeminal plate and globus pallidus, mirroring the basal ganglia pattern seen in occupational exposure.²⁶ The similarities between manganese neurotoxicity and the cognitive and motor changes traditionally attributed to hepatic encephalopathy have led to speculation that manganese accumulation is a contributor to the neurological decline seen in advanced liver disease. Whether this means manganese chelation or dietary manganese restriction should become standard care in liver disease remains an open question, but it underscores a point worth knowing: you do not need to be a welder or drink contaminated water to develop manganese toxicity if your liver is not working properly.